Table 2.
Shift table of functional impairment categories at baseline and week 8 (LOCF) by treatment group
| Week 8 (LOCF) functional impairment | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Placebo n=1,389 | Desvenlafaxine 50 mg/d n=1,411 | Desvenlafaxine 100 mg/d n=555 | |||||||
| Baseline impairment, n (%) | None/mild | Moderate | Marked/extreme | None/mild | Moderate | Marked/extreme | None/mild | Moderate | Marked/extreme |
| Work/studies* | |||||||||
| None/mild | 191 (14.7) | 68 (5.2) | 22 (1.7) | 196 (14.8) | 52 (3.9) | 17 (1.3) | 80 (14.8) | 20 (3.7) | 6 (1.1) |
| Moderate | 197 (15.2) | 187 (14.4) | 67 (5.2) | 273 (20.6) | 182 (13.7) | 44 (3.3) | 103 (19.1) | 65 (12.0) | 20 (3.7) |
| Marked/extreme | 165 (12.7) | 177 (13.7) | 222 (17.1) | 229 (17.3) | 178 (13.4) | 153 (11.6) | 117 (21.7) | 65 (12.0) | 64 (11.9) |
| Social life/leisure activities | |||||||||
| None/mild | 115 (8.3) | 43 (3.1) | 14 (1.0) | 113 (8.0) | 41 (2.9) | 11 (0.8) | 37 (6.7) | 10 (1.8) | 2 (0.4) |
| Moderate | 181 (13.0) | 193 (13.9) | 62 (4.5) | 258 (18.3) | 180 (12.8) | 55 (3.9) | 85 (15.3) | 46 (8.3) | 16 (2.9) |
| Marked/extreme | 226 (16.3) | 230 (16.6) | 325 (23.4) | 298 (21.1) | 232 (16.4) | 223 (15.8) | 140 (25.2) | 117 (21.1) | 102 (18.4) |
| Family life/home responsibilities | |||||||||
| None/mild | 142 (10.2) | 48 (3.5) | 21 (1.5) | 154 (10.9) | 48 (3.4) | 13 (0.9) | 42 (7.6) | 10 (1.8) | 2 (0.4) |
| Moderate | 202 (14.5) | 206 (14.8) | 76 (5.5) | 270 (19.1) | 188 (13.3) | 44 (3.1) | 97 (17.5) | 56 (10.1) | 19 (3.4) |
| Marked/extreme | 201 (14.5) | 228 (16.4) | 265 (19.1) | 274 (19.4) | 216 (15.3) | 204 (14.5) | 133 (24.0) | 106 (19.1) | 90 (16.2) |
*
Work/studies subscale: placebo, n=1,296; desvenlafaxine 50 mg, n=1,324; desvenlafaxine 100 mg, n=540. LOCF=last observation carried forward; SDS=Sheehan Disability Scale.